Oncology Meeting Resources

In this section, you can find all available abstracts, presentations and webcasts on OncologyPRO.

Here below, you can search across all meeting resources by session title, presentation title, presenter or keyword. Results can then be refined by topic, event and publication date.

The use of these presentations is for personal educational purposes only.
ESMO thanks the authors for their generosity.




Format available

Spell check suggestion: did you mean endometrial cervical glynne* vulva* ovarian vaginal* ?

http://oncologypro.esmo.org/Meeting-Resourc...aecological-and-gastrointestinal-cancer-294P

with PM (including 14 ovarian cancer, 4 gastric cancer, 4 colorectal cancer, 1 endometrial cancer, 1 cervical cancer, 1 pancreatic cancer, 1 small bowel cancer and 1 cholangiocellular cancer) were treated ... Hyperthermic intraperitoneal chemotherapy with angiogenesis inhibitors for control of malignant ascites due to gynaecological and gastrointestinal cancer (294P) ... in chronological order. Find out more about our content categorisation . None 0 0 Array All the latest content published on OncologyPRO on the topic of Gastrointestinal Cancers. 0 0 1167606000 Gynaecologic

Date: 18 Nov 2017
Presenter: Lei Wen
Resources: Abstract
Topics: Anti-Cancer Agents & Biologic Therapy, Gastrointestinal Cancers, Gynaecologic Malignancies

http://oncologypro.esmo.org/Meeting-Resourc...cological-cancers-treated-with-selinexor-SEL

§1§Karyopharm, Karyopharm Therapeutics, 02459 - Newton/US, §2§Obstetrics & Gynaecology, University Hospitals Leuven - Campus Gasthuisberg, 3000 - Leuven/BE, §3§Oncology, Aalborg University Hospital ... , BRCA1/2, CDKN2A and pRB. SEL has anti-cancer activity in preclinical models of cervical cancer (CC) & ovarian cancer (OC) and in a phase I clinical study. In an effort to identify markers predictive ... Gynaecologic Malignancies 0 Here below, you will find a list of all the latest content published on this website on the topic of Gynaecologic Malignancies. The content is published in chronological

Date: 08 Oct 2016
Presenter: Marsha Crochiere
Resources: Abstract
Topic: Gynaecologic Malignancies

http://oncologypro.esmo.org/Meeting-Resourc...in-114-patients-with-gynaecological-cancers2

-in-class inhibitor of XPO1, induces nuclear retention & activation of TSPs. This phase 2 trial evaluated the efficacy & tolerability of SEL in pts with metastatic ovarian (OC), cervical (CC) & endometrial (EC) cancers ... Results of a phase 2 trial of selinexor, an oral selective inhibitor of nuclear export (SINE) in 114 patients with gynaecological cancers ... Gynaecological cancers ... Gynaecologic Malignancies 0 Here below, you will find a list of all the latest content published on this website on the topic of Gynaecologic Malignancies. The content is published in chronological

Date: 07 Oct 2016
Presenter: Ignace Vergote
Resources: Abstract, Presentation, Webcast
Topic: Gynaecologic Malignancies

http://oncologypro.esmo.org/Meeting-Resourc...lgian-Gynaecological-Oncology-Group-BGOG-ov5

§1§Gynaecology, UZ Leuven, 3000 - Leuven/BE, §2§., AZ Groeninge, 8500 - Kortrijk/BE, §3§., CHU de Liège, 4000 - Liège/BE, §4§., Grand Hôpital de Charleroi, 6000 - Charleroi/BE, §5§., AZ Nikolaas ... endometrial (EC) or cervical cancer (CC), and no prior weekly or dose-dense TC.

Results

108 (3 cohorts of ovarian, endometrial and cervical cancer of each 36 patients) were included by 12 BGOG ... Gynaecology, UZ Leuven, 3000 - Leuven/BE ... Weekly G-CSF improves the tolerability of weekly paclitaxel-carboplatin. A phase II study of the Belgian Gynaecological Oncology Group (BGOG-ov5)

Date: 27 Sep 2014
Presenter: Ignace Vergote
Resources: Abstract
Topics: Anti-Cancer Agents & Biologic Therapy, Supportive Care